BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25267585)

  • 1. Frequency of TERT promoter mutations in primary tumors of the liver.
    Quaas A; Oldopp T; Tharun L; Klingenfeld C; Krech T; Sauter G; Grob TJ
    Virchows Arch; 2014 Dec; 465(6):673-7. PubMed ID: 25267585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
    Cevik D; Yildiz G; Ozturk M
    World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma.
    Lee SE; Chang SH; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS
    Oncotarget; 2016 Oct; 7(43):69267-69275. PubMed ID: 27661004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.
    Yang X; Guo X; Chen Y; Chen G; Ma Y; Huang K; Zhang Y; Zhao Q; Winkler CA; An P; Lyu J
    Oncotarget; 2016 May; 7(19):27838-47. PubMed ID: 27056898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
    Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
    Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
    Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2017 Feb; 70(3):423-434. PubMed ID: 27634656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.
    Yuan X; Cheng G; Yu J; Zheng S; Sun C; Sun Q; Li K; Lin Z; Liu T; Li P; Xu Y; Kong F; Bjorkholm M; Xu D
    Oncotarget; 2017 Apr; 8(14):23120-23129. PubMed ID: 28416747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
    Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
    Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.
    Lee HW; Park TI; Jang SY; Park SY; Park WJ; Jung SJ; Lee JH
    Medicine (Baltimore); 2017 Feb; 96(5):e5766. PubMed ID: 28151853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
    Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
    Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
    Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of PROX1-mediated TERT expression in hepatitis B viral hepatocellular carcinoma.
    Kim YJ; Yoo JE; Jeon Y; Chong JU; Choi GH; Song DG; Jung SH; Oh BK; Park YN
    Int J Cancer; 2018 Dec; 143(12):3155-3168. PubMed ID: 29987895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients.
    Baudhuin LM; Roberts LR; Enders FT; Swanson RL; Mettler TA; Aderca I; Stadheim LM; Highsmith WE
    J Cancer Res Clin Oncol; 2006 Mar; 132(3):159-62. PubMed ID: 16292541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
    Ko E; Seo HW; Jung ES; Kim BH; Jung G
    Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma.
    Trung NT; Hoan NX; Trung PQ; Binh MT; Van Tong H; Toan NL; Bang MH; Song LH
    Sci Rep; 2020 May; 10(1):8181. PubMed ID: 32424223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly recurrent TERT promoter mutations in human melanoma.
    Huang FW; Hodis E; Xu MJ; Kryukov GV; Chin L; Garraway LA
    Science; 2013 Feb; 339(6122):957-9. PubMed ID: 23348506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
    Nault JC; Mallet M; Pilati C; Calderaro J; Bioulac-Sage P; Laurent C; Laurent A; Cherqui D; Balabaud C; Zucman-Rossi J
    Nat Commun; 2013; 4():2218. PubMed ID: 23887712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Wang Y; Hong Y; Li M; Long J; Zhao YP; Zhang JX; Li Q; You H; Tong WM; Jia JD; Huang J
    PLoS One; 2013; 8(12):e82426. PubMed ID: 24349281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.